New hope for kids with tough brain cancers: triple therapy trial launches
NCT ID NCT07017816
First seen Apr 29, 2026 · Last updated Apr 29, 2026
Summary
This early-phase study tests a new drug (SGT-53) combined with radiation and an immunotherapy drug (Nivolumab) in 18 children whose brain tumors have returned or not responded to standard treatments. The goal is to find the safest dose of SGT-53 and understand its side effects. Researchers will also measure how much of the drug reaches the tumor.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PINEOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.